Comparison of two lung cancer screening scores among patients with chronic obstructive pulmonary disease: A community study.
COPD
epidemiology
lung cancer
screening
Journal
The clinical respiratory journal
ISSN: 1752-699X
Titre abrégé: Clin Respir J
Pays: England
ID NLM: 101315570
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
18
05
2018
revised:
16
10
2018
accepted:
24
12
2018
pubmed:
1
1
2019
medline:
20
8
2019
entrez:
1
1
2019
Statut:
ppublish
Résumé
Based on the National Lung Cancer Screening Trial (NLST), guidelines on screening programs for lung cancer have recommended low-dose computed tomography (LDCT). De Torres et al made a score for COPD patients (COPD-LUCSS) to improve their selection criteria. To examine and compare the discriminating value of both scores in a community-based cohort of COPD patients. Four hundred and twenty-two ever-smokers with COPD from the GenKOLS study in Bergen were merged with the Cancer Registry of Norway. We divided the patients into groups of high and low risk according to the COPD-LUCSS and the NLST criteria. Cox regression and logistic regression were used to analyse the associations between the scores and lung cancer. We used Harrell's C and area under the curve (AUC) to estimate discriminating values and to compare the models. Hazard ratio for the high risk vs the low risk in the COPD-LUCSS was 3.0 (1.4-6.5 95% CI), P < 0.01. Hazard ratio for the NLST criteria was 2.2 (95% CI 1.1-4.5), P < 0.05. Harrell's C was 0.63 for the COPD-LUCSS and 0.59 for the NLST selection criteria. AUC was 0.61 for COPD-LUCSS and 0.59 for NLST criteria. Comparing tests showed no differences (P = 0.76). Although the COPD-LUCSS and the NLST criteria were associated with increased risk of lung cancer, the AUC and Harrell's C values showed that these models have poor discriminating abilities in our cohort of COPD patients. The COPD-LUCSS was not significantly better than the NLST criteria.
Types de publication
Comparative Study
Journal Article
Langues
eng
Pagination
114-119Subventions
Organisme : GlaxoSmithKline Research & Development Limited
Informations de copyright
© 2018 John Wiley & Sons Ltd.